Abstract
Drug development in diabetes and obesity is a rapidly changing research field. Although the diabetes and obesity disease cluster is currently dominated by therapeutics indicated for diabetes, many anti-obesity compounds are in various stages of development and target several promising mechanisms involved in body weight regulation, particularly those linked to central appetite function. In addition, there is a considerable focus on advancing drug treatment concepts in disease-related liver complications, notably nonalcoholic steatohepatitis (NASH). Animal models of diabetes and obesity play a pivotal role in the exploration of the underlying disease mechanisms and have proven to be highly instrumental in preclinical target discovery and drug development. Most of the current disease mechanistic knowledge has arisen from research employing mouse and rat models that mimic the human condition in varying degree. The disease models are based on various experimental manipulations, including dietary concepts, genetic modifications, chemotoxins and surgical approaches. The rodent models employed in preclinical drug development for type 2 diabetes and obesity exhibit both distinct and overlapping pathology. Due to their individual clinical and histopathological phenotype, diabetes and obesity models also differ with respect to clinical translatability which has important implications for their applicability in preclinical drug development. With the aim to guide researchers in the selection of appropriate rodent models for testing drug candidates in preclinical development for diabetes and obesity, we here evaluate the most prevalent rodent models employed in type 2 diabetes and obesity research. In addition, we review current rodent models applicable for probing effects of therapeutic drug concepts in NASH.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Wilmot E, Idris I. Early onset type 2 diabetes: risk factors, clinical impact and management. Ther Adv Chronic Dis. 2014;5:234–44.
Lascar N, Brown J, Pattison H, et al. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2017;6:69–80.
Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–10.
Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42:563–70.
International Diabetes Federation. IDF diabetes atlas. http://www.diabetesatlas.org/. 2015
Fazel Y, Koenig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017–25.
Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Prim. 2015;1:15018.
Mandavia CH, Pulakat L, DeMarco V, et al. Over-nutrition and metabolic cardiomyopathy. Metabolism. 2012;61:1205–10.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–65.
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–90.
Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147–1159e5.
Sanyal A, Ratziu V, Harrison S, et al. Cenicriviroc versus placebo for the treatment of nonalcoholic steatohepatitis with liver fibrosis: results from the year 1 primary analysis of the phase 2b CENTAUR study. Hepatology. 2016;64:1118.
Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.
Moller DE. Metabolic disease drug discovery – “hitting the target” is easier said than done. Cell Metab. 2012;15:19–24.
Chandrasekera PC, Pippin JJ. Of rodents and men: species-specific glucose regulation and type 2 diabetes research. ALTEX. 2014;31:157–76.
Vickers SP, Jackson HC, Cheetham SC. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol. 2011;164:1248–62.
Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nat Rev Neurosci. 2014;15:367–78.
Ryan KK, Woods SC, Seeley RJ. Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity. Cell Metab. 2012;15:137–49.
Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707–18.
Kinsey-Jones JS, Murphy KG. Current models and strategies in the development of antiobesity drugs. Ann N Y Acad Sci. 2011;1245:3–6.
DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Prim. 2015;1:15019.
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.
Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.
Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl 4):32–42.
Mezza T, Muscogiuri G, Sorice GP, et al. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes. 2014;63:994–1007.
Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66:241–55.
Saisho Y, Butler AE, Manesso E, et al. β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36:111–7.
Yoneda S, Uno S, Iwahashi H, et al. Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. J Clin Endocrinol Metab. 2013;98:2053–61.
Chen C, Cohrs CM, Stertmann J, et al. Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab. 2017;6:943–57.
Marchetti P, Lupi R, Del Guerra S, et al. The β-Cell in human type 2 diabetes. Adv Exp Med Biol. 2010;654:501–14.
American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40:S11–24.
Bailey CJ, Tahrani AA, Barnett AH. Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes Endocrinol. 2016;4:350–9.
Tritschler S, Theis FJ, Lickert H, et al. Systematic single-cell analysis provides new insights into heterogeneity and plasticity of the pancreas. Mol Metab. 2017;6:974–90.
King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166:877–94.
Van Belle TL, Taylor P, von Herrath MG. Mouse models for type 1 diabetes. Drug Discov Today Dis Model. 2009;6:41–5.
Myers MG, Leibel RL, Seeley RJ, et al. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010;21:643–51.
Dietrich MO, Horvath TL. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov. 2012;11:675–91.
Cui H, López M, Rahmouni K. The cellular and molecular bases of leptin and ghrelin resistance in obesity. Nat Rev Endocrinol. 2017;13:338–51.
Farooqi IS, Keogh JM, Kamath S, et al. Partial leptin deficiency and human adiposity. Nature. 2001;414:34–5.
Clément K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392:398–401.
Strobel A, Issad T, Camoin L, et al. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18:213–5.
Farooqi IS, O’Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014;223:T63–70.
Funcke J-B, von Schnurbein J, Lennerz B, et al. Monogenic forms of childhood obesity due to mutations in the leptin gene. Mol Cell Pediatr. 2014;1:3.
Jafar-Mohammadi B, McCarthy MI. Genetics of type 2 diabetes mellitus and obesity—a review. Ann Med. 2008;40:2–10.
Mahajan A, Go MJ, Zhang W, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46:234–44.
Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153:1127–8.
Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995;83:1263–71.
Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84:491–5.
Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978;14:141–8.
Puff R, Dames P, Weise M, et al. Reduced proliferation and a high apoptotic frequency of pancreatic beta cells contribute to genetically-determined diabetes susceptibility of db/db BKS mice. Horm Metab Res. 2011;43:306–11.
Sullivan KA, Hayes JM, Wiggin TD, et al. Mouse models of diabetic neuropathy. Neurobiol Dis. 2007;28:276–85.
Trak-Smayra V, Paradis V, Massart J, et al. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol. 2011;92:413–21.
Coleman DL, Hummel KP. Hyperinsulinemia in pre-weaning diabetes (db) mice. Diabetologia. 1974;10(Suppl):607–10.
Dalbøge LS, Almholt DLC, Neerup TSR, et al. Characterisation of age-dependent beta cell dynamics in the male db/db mice. PLoS One. 2013;8:e82813.
Do OH, Gunton JE, Gaisano HY, et al. Changes in beta cell function occur in prediabetes and early disease in the Lepr db mouse model of diabetes. Diabetologia. 2016;59:1222–30.
Boland BB, Brown C, Boland ML, et al. Pancreatic β-cell rest replenishes insulin secretory capacity and attenuates diabetes in an extreme model of obese type 2 diabetes. Diabetes. 2019;68:131–40.
Shimoda M, Kanda Y, Hamamoto S, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011;54:1098–108.
Dor Y, Brown J, Martinez OI, et al. Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 2004;429:41–6.
Kanda Y, Shimoda M, Tawaramoto K, et al. Molecular analysis of db gene-related pancreatic beta cell dysfunction; evidence for a compensatory mechanism inhibiting development of diabetes in the db gene heterozygote. Endocr J. 2009;56:997–1008.
Kawasaki F, Matsuda M, Kanda Y, et al. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab. 2005;288:E510–8.
Medarova Z, Bonner-Weir S, Lipes M, et al. Imaging beta-cell death with a near-infrared probe. Diabetes. 2005;54:1780–8.
Dalbøge LS, Almholt DLC, Neerup TSR, et al. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases $β$-cell mass without affecting islet number in db/db Mice. J Pharmacol Exp Ther. 2014;350:353–60.
van Witteloostuijn SB, Dalbøge LS, Hansen G, et al. GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice. J Pept Sci. 2017;23:845–54.
Jurczak MJ, Lee H-Y, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function. Diabetes. 2011;60:890–8.
Kanda Y, Shimoda M, Hamamoto S, et al. Molecular mechanism by which pioglitazone preserves pancreatic -cells in obese diabetic mice: evidence for acute and chronic actions as a PPAR agonist. AJP Endocrinol Metab. 2010;298:E278–86.
Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 2002;45:1263–73.
Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med. 1983;173:68–75.
Peterson RG, Shaw WN, Neel MA, et al. Zucker diabetic fatty rat as a model for non-insulin dependent diabetes mellitus. Inst Lab Anim Res News. 1990;32:16–9.
Phillips MS, Liu Q, Hammond HA, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet. 1996;13:18–9.
Etgen GJ, Oldham BA. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism. 2000;49:684–8.
Topp BG, Atkinson LL, Finegood DT. Dynamics of insulin sensitivity, beta-cell function, and beta-cell mass during the development of diabetes in fa/fa rats. Am J Physiol Endocrinol Metab. 2007;293:E1730–5.
Vrang N, Jelsing J, Simonsen L, et al. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab. 2012;303:E253–64.
Wang X, DuBois DC, Sukumaran S, et al. Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals. Diabetes Metab Syndr Obes. 2014;7:531–41.
Nawano M, Oku A, Ueta K, et al. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab. 2000;278:E535–43.
Tokuyama Y, Sturis J, DePaoli AM, et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes. 1995;44:1447–57.
Griffen SC, Wang J, German MS. A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes. 2001;50:63–8.
Lee Y, Lingvay I, Szczepaniak LS, et al. Pancreatic steatosis: harbinger of type 2 diabetes in obese rodents. Int J Obes. 2010;34:396–400.
Poitout V. Beta-cell lipotoxicity: burning fat into heat? Endocrinology. 2004;145:3563–5.
Choe SS, Choi AH, Lee J-W, et al. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic -cells. Diabetes. 2007;56:1534–43.
Hansen HH, Jelsing J, Hansen CF, et al. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male Zucker diabetic fatty rat. J Pharmacol Exp Ther. 2014;350:657–64.
Paulsen SJ, Vrang N, Larsen LK, et al. Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat. 2010;217:624–30.
Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47:358–64.
Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes. 1995;44:249–56.
Cummings BP, Digitale EK, Stanhope KL, et al. Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am J Physiol Integr Comp Physiol. 2008;295:R1782–93.
Cummings BP, Stanhope KL, Graham JL, et al. Dietary fructose accelerates the development of diabetes in UCD-T2DM rats: amelioration by the antioxidant, α-lipoic acid. Am J Physiol Integr Comp Physiol. 2010;298:R1343–50.
Cummings BP, Bettaieb A, Graham JL, et al. Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats. Proc Natl Acad Sci. 2011;108:14670–5.
Rountree AM, Reed BJ, Cummings BP, et al. Loss of coupling between calcium influx, energy consumption and insulin secretion associated with development of hyperglycaemia in the UCD-T2DM rat model of type 2 diabetes. Diabetologia. 2013;56:803–13.
Li X, Zhang L, Meshinchi S, et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes. 2006;55:2965–73.
Cummings BP, Stanhope KL, Graham JL, et al. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes. 2010;59:2653–61.
Cummings BP, Bettaieb A, Graham JL, et al. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. J Endocrinol. 2014;221:133–44.
Levin BE, Dunn-Meynell AA, Balkan B, et al. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Phys. 1997;273:R725–30.
Peterson RG, Jackson CV, Zimmerman K, et al. Characterization of the ZDSD rat: a translational model for the study of metabolic syndrome and type 2 diabetes. J Diabetes Res. 2015;2015:1–10.
Davidson EP, Coppey LJ, Holmes A, et al. Characterization of diabetic neuropathy in the Zucker diabetic Sprague-Dawley rat: a new animal model for type 2 diabetes. J Diabetes Res. 2014;2014:1–7.
Kawano K, Hirashima T, Mori S, et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41:1422–8.
Man ZW, Zhu M, Noma Y, et al. Impaired beta-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM. Diabetes. 1997;46:1718–24.
Yamada T, Kose H, Ohta T, et al. Genetic dissection of complex genetic factor involved in NIDDM of OLETF rat. Exp Diabetes Res. 2012;2012:1–6.
Funakoshi A, Miyasaka K, Jimi A, et al. Little or no expression of the cholecystokinin-A receptor gene in the pancreas of diabetic rats (Otsuka Long-Evans Tokushima Fatty = OLETF Rats). Biochem Biophys Res Commun. 1994;199:482–8.
Moran TH, Katz LF, Plata-Salaman CR, et al. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Phys. 1998;274:R618–25.
Takiguchi S, Takata Y, Funakoshi A, et al. Disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. Gene. 1997;197:169–75.
Dockray GJ. Cholecystokinin and gut–brain signalling. Regul Pept. 2009;155:6–10.
Dockray GJ. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes. 2012;19:8–12.
Koh EH, Kim M-S, Park J-Y, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes. 2003;52:2331–7.
Shin SJ, Chung S, Kim SJ, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11:e0165703.
Kosegawa I, Katayama S, Kikuchi C, et al. Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens Res. 1996;19:37–41.
Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med. 1976;119:85–90.
Guenifi A, Abdel-Halim SM, Höög A, et al. Preserved beta-cell density in the endocrine pancreas of young, spontaneously diabetic Goto-Kakizaki (GK) rats. Pancreas. 1995;10:148–53.
Movassat J, Saulnier C, Serradas P, et al. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia. 1997;40:916–25.
Hughes SJ, Suzuki K, Goto Y. The role of islet secretory function in the development of diabetes in the GK Wistar rat. Diabetologia. 1994;37:863–70.
Standaert ML, Sajan MP, Miura A, et al. Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states. J Biol Chem. 2004;279:24929–34.
Koyama M, Wada R, Sakuraba H, et al. Accelerated loss of islet beta cells in sucrose-fed Goto-Kakizaki rats, a genetic model of non-insulin-dependent diabetes mellitus. Am J Pathol. 1998;153:537–45.
Portha B, Serradas P, Bailbé D, et al. Beta-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes. 1991;40:486–91.
Bisbis S, Bailbe D, Tormo MA, et al. Insulin resistance in the GK rat: decreased receptor number but normal kinase activity in liver. Am J Physiol Metab. 1993;265:E807–13.
Miralles F, Portha B. Early development of beta-cells is impaired in the GK rat model of type 2 diabetes. Diabetes. 2001;50(Suppl 1):S84–8.
Movassat J, Calderari S, Fernández E, et al. Type 2 diabetes – a matter of failing beta-cell neogenesis? Clues from the GK rat model. Diabetes Obes Metab. 2007;9(Suppl 2):187–95.
Gauguier D, Froguel P, Parent V, et al. Chromosomal mapping of genetic loci associated with non-insulin dependent diabetes in the GK rat. Nat Genet. 1996;12:38–43.
Tourrel C, Bailbe D, Lacorne M, et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002;51:1443–52.
Inaba W, Mizukami H, Kamata K, et al. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol. 2012;691:297–306.
Simonsen L, Pilgaard S, Orskov C, et al. Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats. Diabetes Obes Metab. 2009;11:884–90.
Nakamura M, Yamada K. Studies on a diabetic (KK) strain of the mouse. Diabetologia. 1967;3:212–21.
Matsuo T, Shino A, Iwatsuka H, et al. Induction of overt diabetes in KK mice by dietary means. Endocrinol Jpn. 1970;17:477–88.
Miltenberger RJ, Mynatt RL, Wilkinson JE, et al. The role of the agouti gene in the yellow obese syndrome. J Nutr. 1997;127:1902S–7S.
Lu D, Willard D, Patel IR, et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature. 1994;371:799–802.
Ebihara K, Ogawa Y, Katsuura G, et al. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes. 1999;48:2028–33.
Suto J, Matsuura S, Imamura K, et al. Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice. Eur J Endocrinol. 1998;139:654–61.
Halaas JL, Boozer C, Blair-West J, et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A. 1997;94:8878–83.
Iwatsuka H, Shino A, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn. 1970;17:23–35.
Diani AR, Sawada GA, Hannah BA, et al. Analysis of pancreatic islet cells and hormone content in the spontaneously diabetic KKAy mouse by morphometry, immunocytochemistry and radioimmunoassay. Virchows Arch A Pathol Anat Histopathol. 1987;412:53–61.
Kimura M, Suzuki J, Amemiya K. A genetically diabetic model “KK-CAy mice” for a pharmacological assay. Endocrinol Jpn. 1979;26:185–95.
Rhee S, Sung Y, Lee Y, et al. Obesity of TallyHO/JngJ mouse is due to increased food intake with early development of leptin resistance. Exp Clin Endocrinol Diabetes. 2010;119:243–51.
Parkman J, Mao X, Dillon K, et al. Genotype-dependent metabolic responses to semi-purified high-sucrose high-fat diets in the TALLYHO/Jng vs. C57BL/6 mouse during the development of obesity and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2016;124:622–9.
Kim JH, Stewart TP, Soltani-Bejnood M, et al. Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J Endocrinol. 2006;191:437–46.
Ostler JE, Maurya SK, Dials J, et al. Effects of insulin resistance on skeletal muscle growth and exercise capacity in type 2 diabetic mouse models. Am J Physiol Metab. 2014;306:E592–605.
Kim JH, Sen S, Avery CS, et al. Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics. 2001;74:273–86.
Denvir J, Boskovic G, Fan J, et al. Whole genome sequence analysis of the TALLYHO/Jng mouse. BMC Genomics. 2016;17:907.
Franko A, Neschen S, Rozman J, et al. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice. Mol Metab. 2017;6:256–66.
Neschen S, Scheerer M, Seelig A, et al. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes. 2015;64:284–90.
Bielschowsky F, Bielschowsky M. The New Zealand strain of obese mice; their response to stilboestrol and to insulin. Aust J Exp Biol Med Sci. 1956;34:181–98.
Proietto J, Larkins RG. A perspective on the New Zealand obese mouse. In: Shafrir E, editor. Lessons from animal models of diabetes, vol. 4. London: Smith-Gordon; 1993. p. 65–73.
Leiter EH, Reifsnyder PC, Flurkey K, et al. NIDDM genes in mice: deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes. 1998;47:1287–95.
Haskell BD, Flurkey K, Duffy TM, et al. The diabetes-prone NZO/HlLt strain. I. Immunophenotypic comparison to the related NZB/BlNJ and NZW/LacJ strains. Lab Investig. 2002;82:833–42.
Cho Y-R, Kim H-J, Park S-Y, et al. Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes. Am J Physiol Metab. 2007;293:E327–36.
Kluth O, Matzke D, Kamitz A, et al. Identification of four mouse diabetes candidate genes altering β-cell proliferation. PLoS Genet. 2015;11:e1005506.
Taylor BA, Wnek C, Schroeder D, et al. Multiple obesity QTLs identified in an intercross between the NZO (New Zealand obese) and the SM (small) mouse strains. Mamm Genome. 2001;12:95–103.
Jürgens HS, Schürmann A, Kluge R, et al. Hyperphagia, lower body temperature, and reduced running wheel activity precede development of morbid obesity in New Zealand obese mice. Physiol Genomics. 2006;25:234–41.
Herberg L, Major E, Hennigs U, et al. Differences in the development of the obese-hyperglycemic syndrome in obob and NZO mice. Diabetologia. 1970;6:292–9.
Jürgens HS, Neschen S, Ortmann S, et al. Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction. Diabetologia. 2007;50:1481–9.
Igel M, Becker W, Herberg L, et al. Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology. 1997;138:4234–9.
Veroni MC, Proietto J, Larkins RG. Evolution of insulin resistance in New Zealand obese mice. Diabetes. 1991;40:1480–7.
Melez KA, Harrison LC, Gilliam JN, et al. Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes. 1980;29:835–40.
Kluth O, Mirhashemi F, Scherneck S, et al. Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. Diabetologia. 2011;54:605–16.
Laeger T, Baumeier C, Wilhelmi I, et al. FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. Diabetologia. 2017;60:2274–84.
Schwenk RW, Baumeier C, Finan B, et al. GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia. 2015;58:604–14.
Leiter EH, Reifsnyder PC, Zhang W, et al. Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes. Endocrinology. 2006;147:919–26.
Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol. 2001;18:247–56.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50:537–46.
Cunningham VJ, Rabiner EA, Slifstein M, et al. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46–50.
Malaisse WJ. Alloxan toxicity to the pancreatic B-cell. A new hypothesis. Biochem Pharmacol. 1982;31:3527–34.
Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015;70:5.47.1–20.
Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51:216–26.
Cardinal JW, Allan DJ, Cameron DP. Differential metabolite accumulation may be the cause of strain differences in sensitivity to streptozotocin-induced β cell death in inbred mice. Endocrinology. 1998;139:2885–91.
Ostenson CG, Grill V, Roos M. Studies on sex dependency of B-cell susceptibility to streptozotocin in a rat model of type II diabetes mellitus. Exp Clin Endocrinol. 1989;93:241–7.
Masiello P, De Paoli A, Bergamini E. Age-Dependent changes in the sensitivity of the rat to a diabetogenic agent (streptozotocin). Endocrinology. 1975;96:787–9.
Bonner-Weir S, Trent DF, Honey RN, et al. Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes. 1981;30:64–9.
Portha B, Picon L, Rosselin G. Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia. 1979;17:371–7.
Kataoka M, Kawamuro Y, Shiraki N, et al. Recovery from diabetes in neonatal mice after a low-dose streptozotocin treatment. Biochem Biophys Res Commun. 2013;430:1103–8.
Portha B, Kergoat M. Dynamics of glucose-induced insulin release during the spontaneous remission of streptozocin diabetes induced in the newborn rat. Diabetes. 1985;34:574–9.
Grill V, Westberg M, Ostenson CG. B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia. J Clin Invest. 1987;80:664–9.
Welsh N, Hellerström C. In vitro restoration of insulin production in islets from adult rats treated neonatally with streptozotocin. Endocrinology. 1990;126:1842–8.
Nørgaard SA, Sand FW, Sørensen DB, et al. Softened food reduces weight loss in the streptozotocin-induced male mouse model of diabetic nephropathy. Lab Anim. 2018;52:373–83.
Bolzán AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res. 2002;512:121–34.
Reed M, Meszaros K, Entes L, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism. 2000;49:1390–4.
Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52:313–20.
Gheibi S, Kashfi K, Ghasemi A. A practical guide for induction of type-2 diabetes in rat: incorporating a high-fat diet and streptozotocin. Biomed Pharmacother. 2017;95:605–13.
World Health Organization. Obesity and overweight Fact sheet. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. 2017.
Loos RJF, Janssens ACJW. Predicting polygenic obesity using genetic information. Cell Metab. 2017;25:535–43.
Clemmensen C, Müller TD, Woods SC, et al. Gut-brain cross-talk in metabolic control. Cell. 2017;168:758–74.
Brockmann GA, Bevova MR. Using mouse models to dissect the genetics of obesity. Trends Genet. 2002;18:367–76.
Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol. 2006;15:318–30.
Dalbøge LS, Pedersen PJ, Hansen G, et al. A hamster model of diet-induced obesity for preclinical evaluation of anti-obesity, anti-diabetic and lipid modulating agents. PLoS One. 2015;10:e0135634.
West DB, Boozer CN, Moody DL, et al. Dietary obesity in nine inbred mouse strains. Am J Physiol Integr Comp Physiol. 1992;262:R1025–32.
Montgomery MK, Hallahan NL, Brown SH, et al. Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding. Diabetologia. 2013;56:1129–39.
Marques C, Meireles M, Norberto S, et al. High-fat diet-induced obesity Rat model: a comparison between Wistar and Sprague-Dawley Rat. Adipocytes. 2016;5:11–21.
Hansen G, Jelsing J, Vrang N. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats. Acta Pharmacol Sin. 2012;33:194–200.
Axel AMD, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010;35:1464–76.
Dalbøge LS, Pedersen SL, van Witteloostuijn SB, et al. Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake. J Pept Sci. 2015;21:85–94.
Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight. Diabetes Obes Metab. 2012;14:531–8.
Lachey JL, D’Alessio DA, Rinaman L, et al. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology. 2005;146:458–62.
Al-Saffar A, da Costa AN, Delaunois A, et al. Gastrointestinal safety pharmacology in drug discovery and development. In: Pugsley M, Curtis M, editors. Principles of safety pharmacology. Handbook of experimental pharmacology, vol. 229. Berlin/Heidelberg: Springer; 2015. p. 291–321.
MacLean PS, Bergouignan A, Cornier M-A, et al. Biology’s response to dieting: the impetus for weight regain. Am J Physiol Integr Comp Physiol. 2011;301:R581–600.
Ratner C, Madsen AN, Kristensen LV, et al. Impaired oxidative capacity due to decreased CPT1b levels as a contributing factor to fat accumulation in obesity. Am J Physiol Integr Comp Physiol. 2015;308:R973–82.
Polidori D, Sanghvi A, Seeley RJ, et al. How strongly does appetite counter weight loss? quantification of the feedback control of human energy intake. Obesity (Silver Spring). 2016;24:2289–95.
Kitka T, Tuza S, Varga B, et al. Differential regulation of metabolic parameters by energy deficit and hunger. Metabolism. 2015;64:1235–9.
Buettner R, Schölmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity. 2007;15:798–808.
Sato Mito N, Suzui M, Yoshino H, et al. Long term effects of high fat and sucrose diets on obesity and lymphocyte proliferation in mice. J Nutr Health Aging. 2009;13:602–6.
Shapiro A, Mu W, Roncal C, et al. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1370–5.
Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 2010;151:2040–9.
Rothwell NJ, Stock MJ. The cafeteria diet as a tool for studies of thermogenesis. J Nutr. 1988;118:925–8.
Nicola SM. Reassessing wanting and liking in the study of mesolimbic influence on food intake. Am J Physiol Integr Comp Physiol. 2016;311:R811–40.
Liu C, Lee S, Elmquist JK. Circuits controlling energy balance and mood: inherently intertwined or just complicated intersections? Cell Metab. 2014;19:902–9.
Kelley AE, Baldo BA, Pratt WE. A proposed hypothalamic-thalamic-striatal axis for the integration of energy balance, arousal, and food reward. J Comp Neurol. 2005;493:72–85.
Clifton PG. Neural circuits of eating behaviour: opportunities for therapeutic development. J Psychopharmacol. 2017;31:1388–402.
Meye FJ, Adan RAH. Feelings about food: the ventral tegmental area in food reward and emotional eating. Trends Pharmacol Sci. 2014;35:31–40.
Nathan PJ, Bullmore ET. From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol. 2009;12:995.
Hansen TT, Jakobsen TA, Nielsen MS, et al. Hedonic changes in food choices following Roux-en-Y gastric bypass. Obes Surg. 2016;26:1946–55.
Hansen HH, Jensen MM, Overgaard A, et al. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacol Biochem Behav. 2013;110:265–71.
Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310:R885–95.
Barkholt P, Pedersen PJ, Hay-Schmidt A, et al. Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass. Mol Metab. 2016;5:296–304.
Boyle CN, Lutz TA, Le Foll C. Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018;8:203–10.
la Fleur SE, Luijendijk MCM, van der Zwaal EM, et al. The snacking rat as model of human obesity: effects of a free-choice high-fat high-sugar diet on meal patterns. Int J Obes. 2014;38:643–9.
Martire SI, Holmes N, Westbrook RF, et al. Altered feeding patterns in rats exposed to a palatable cafeteria diet: increased snacking and its implications for development of obesity. PLoS One. 2013;8:e60407.
Bake T, Hellgren KT, Dickson SL. Acute ghrelin changes food preference from a high-fat diet to chow during binge-like eating in rodents. J Neuroendocrinol. 2017;29:1–12.
Hansen HH, Hansen G, Tang-Christensen M, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010;636:88–95.
Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered. 1950;41:317–8.
Mayer J, Bates MW, Dickie MM. Hereditary diabetes in genetically obese mice. Science. 1951;113:746–7.
Coleman DL, Hummel KP. The influence of genetic background on the expression of the obese (Ob) gene in the mouse. Diabetologia. 1973;9:287–93.
Dubuc PU. The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism. 1976;25:1567–74.
Ludwig S, Muller-Wieland D, Goldstein BJ, et al. The insulin receptor gene and its expression in insulin-resistant mice. Endocrinology. 1988;123:594–600.
Garthwaite TL, Martinson DR, Tseng LF, et al. A longitudinal hormonal profile of the genetically obese mouse. Endocrinology. 1980;107:671–6.
Tomita T, Doull V, Pollock HG, et al. Pancreatic islets of obese hyperglycemic mice (ob/ob). Pancreas. 1992;7:367–75.
Irles E, Ñeco P, Lluesma M, et al. Enhanced glucose-induced intracellular signaling promotes insulin hypersecretion: pancreatic beta-cell functional adaptations in a model of genetic obesity and prediabetes. Mol Cell Endocrinol. 2015;404:46–55.
Bock T, Pakkenberg B, Buschard K. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes. 2003;52:1716–22.
Flowers JB, Rabaglia ME, Schueler KL, et al. Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes. 2007;56:1228–39.
Menahan LA. Age-related changes in lipid and carbohydrate metabolism of the genetically obese mouse. Metabolism. 1983;32:172–8.
Lindström P. β-cell function in obese-hyperglycemic mice [ob/ob Mice]. In: Islam MS, editor. The Islets of Langerhans, Advances in experimental medicine and biology, vol. 654. Berlin/Heidelberg: Springer; 2010. p. 463–77.
Garris DR, Garris BL. Cytochemical analysis of pancreatic islet hypercytolipidemia following diabetes (db/db) and obese (ob/ob) mutation expression: influence of genomic background. Pathobiology. 2004;71:231–40.
McQuaid TS, Saleh MC, Joseph JW, et al. cAMP-mediated signaling normalizes glucose-stimulated insulin secretion in uncoupling protein-2 overexpressing beta-cells. J Endocrinol. 2006;190:669–80.
Hellman B. Studies in obese-hyperglycemic mice. Ann N Y Acad Sci. 1965;131:541–58.
Hahn HJ, Hellman B, Lernmark A, et al. The pancreatic beta-cell recognition of insulin secretogogues. Influence of neuraminidase treatment on the release of insulin and the islet content of insulin, sialic acid, and cyclic adenosine 3′:5′-monophosphate. J Biol Chem. 1974;249:5275–84.
Edvell A, Lindström P. Development of insulin secretory function in young obese hyperglycemic mice (Umeå ob/ob). Metabolism. 1995;44:906–13.
Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540–3.
Weigle DS, Bukowski TR, Foster DC, et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest. 1995;96:2065–70.
D’souza AM, Asadi A, Johnson JD, et al. Leptin deficiency in rats results in hyperinsulinemia and impaired glucose homeostasis. Endocrinology. 2014;155:1268–79.
Chua SC, White DW, Wu-Peng XS, et al. Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes. 1996;45:1141–3.
Crouse JA, Elliott GE, Burgess TL, et al. Altered cell surface expression and signaling of leptin receptors containing the fatty mutation. J Biol Chem. 1998;273:18365–73.
Yamashita T, Murakami T, Iida M, et al. Leptin receptor of Zucker fatty rat performs reduced signal transduction. Diabetes. 1997;46:1077–80.
Zucker LM, Zucker TF. Fatty, a new mutation in the rat. J Hered. 1961;52:275–8.
Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat. Endocrinology. 1972;90:1320–30.
Augstein P, Salzsieder E. Morphology of pancreatic islets: a time course of pre-diabetes in Zucker fatty rats. In: Stocker C, editor. Type 2 diabetes, methods in molecular biology, vol. 560. Berlin/Heidelberg: Springer; 2009. p. 159–89.
Leonard BL, Watson RN, Loomes KM, et al. Insulin resistance in the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes. Acta Diabetol. 2005;42:162–70.
Ikeda H, Shino A, Matsuo T, et al. A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes. 1981;30:1045–50.
Durham HA, Truett GE. Development of insulin resistance and hyperphagia in Zucker fatty rats. AJP Regul Integr Comp Physiol. 2005;290:R652–8.
Bremond J, Bonte D, Orosco M, et al. Variations of plasma lipid fractions in relation to age in two models of obesity. Int J Obes. 1983;7:467–75.
Abadie JM, Malcom GT, Porter JR, et al. Can associations between free fatty acid levels and metabolic parameters determine insulin resistance development in obese Zucker rats? Life Sci. 2001;69:2675–83.
Maher MA, Banz WJ, Zemel MB. Variations of blood pressures in lean Zucker rats fed low or high fat diets. J Nutr. 1995;125:2618–22.
Maher MA, Banz WJ, Truett GE, et al. Dietary fat and sex modify heterozygote effects of the rat fatty (fa) allele. J Nutr. 1996;126:2487–93.
Fellmann L, Nascimento AR, Tibiriça E, et al. Murine models for pharmacological studies of the metabolic syndrome. Pharmacol Ther. 2013;137:331–40.
Peterson RG, Van Jackson C, Zimmerman KM, et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse. PLoS One. 2017;12:e0179856.
Droz BA, Sneed BL, Jackson CV, et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco mouse. PLoS One. 2017;12:e0179808.
Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7(Suppl 2):765–70.
Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37:85–9.
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2016;14:32–42.
Rosso N, Chavez-Tapia NC, Tiribelli C, et al. Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol. 2014;20:9038–49.
Berlanga A, Guiu-Jurado E, Porras JA, et al. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221–39.
Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.
Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397–411.
Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387–400.
Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic Fatty liver disease. Gastroenterology. 2015;149:389–397.e10.
Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656–65.
Agopian VG, Kaldas FM, Hong JC, et al. Liver transplantation for nonalcoholic steatohepatitis. Ann Surg. 2012;256:624–33.
Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
Patel NS, Doycheva I, Peterson MR, et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:561–568.e1.
Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology. 2016;63:2032–43.
Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249–74.
Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 2014;9:e115922.
Farrell GC, Mridha AR, Yeh MM, et al. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. Liver Int. 2014;34:1084–93.
Clapper JR, Hendricks MD, Gu G, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. AJP Gastrointest Liver Physiol. 2013;305:G483–95.
Haczeyni F, Poekes L, Wang H, et al. Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity (Silver Spring). 2017;25:155–65.
Kristiansen MNB, Veidal SS, Rigbolt KTG, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol. 2016;8:673.
Tølbøl KS, Kristiansen MN, Hansen HH, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24:179–94.
Roth JD, Feigh M, Veidal SS, et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24:195–210.
Sanches SCL, Ramalho LNZ, Augusto MJ, et al. Nonalcoholic steatohepatitis: a search for factual animal models. Biomed Res Int. 2015;2015:1–13.
Delire B, Stärkel P, Leclercq I. Animal models for fibrotic liver diseases: what we have, what we need, and what is under development. J Clin Transl Hepatol. 2015;3:53–66.
Carino A, Cipriani S, Marchianò S, et al. BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci Rep. 2017;7:42801.
Lieber CS, Leo MA, Mak KM, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr. 2004;79:502–9.
Valdecantos MP, Pardo V, Ruiz L, et al. A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatology. 2017;65:950–68.
Kucera O, Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol. 2014;20:8364.
Van Rooyen DM, Gan LT, Yeh MM, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol. 2013;59:144–52.
van Koppen A, Verschuren L, van den Hoek AM, et al. Uncovering a predictive molecular signature for the onset of NASH-related fibrosis in a translational NASH mouse model. Cell Mol Gastroenterol Hepatol. 2018;5:83–98.e10.
Kristiansen MNB, Veidal SS, Rigbolt KTG, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol. 2016:8, 673–684.
Trevaskis JL, Griffin PS, Wittmer C, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. AJP Gastrointest Liver Physiol. 2012;302:G762–72.
Jouihan H, Will S, Guionaud S, et al. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Mol Metab. 2017;6:1360–70.
Ding Z-M, Xiao Y, Wu X, et al. Progression and regression of hepatic lesions in a mouse model of NASH induced by dietary intervention and its implications in pharmacotherapy. Front Pharmacol. 2018;9:410.
Honda Y, Imajo K, Kato T, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One. 2016;11:e0146337.
Boland ML, Oldham S, Boland BB, et al. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction. World J Gastroenterol. 2018;24:1748–65.
Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Liver Physiol. 2011;301:G825–34.
Krishnan A, Abdullah TS, Mounajjed T, et al. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017;312:G666–80.
Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65:579–88.
Filozof C, Chow S-C, Dimick-Santos L, et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic. Hepatol Commun. 2017;1:577–85.
Tølbøl KS, Stierstorfer B, Rippmann JF, et al. Disease progression and pharmacological intervention in a nutrient-deficient rat model of nonalcoholic steatohepatitis. Dig Dis Sci. 2018. In press.
Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94:93–103.
Nakae D. Endogenous liver carcinogenesis in the rat. Pathol Int. 1999;49:1028–42.
Kirsch RRER, Clarkson V, Shephard EG, et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol. 2003;18:1272–82.
Weber LWD, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33:105–36.
Wallace M, Hamesch K, Lunova M, et al. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Lab Anim. 2015;49:21–9.
Jenkins SA, Grandison A, Baxter JN, et al. A dimethylnitrosamine-induced model of cirrhosis and portal hypertension in the rat. J Hepatol. 1985;1:489–99.
Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141–52.
Kim YO, Popov Y, Schuppan D. Optimized mouse models for liver fibrosis. In: Clausen BE, Laman JD, editors. Inflammation. Methods and protocols, vol. 1559. Berlin/Heidelberg: Springer; 2017. p. 279–96.
Gu K, Zhao J-D, Ren Z-G, et al. A natural process of cirrhosis resolution and deceleration of liver regeneration after thioacetamide withdrawal in a rat model. Mol Biol Rep. 2011;38:1687–96.
Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69:385–95.
Kubota N, Kado S, Kano M, et al. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice. Clin Exp Pharmacol Physiol. 2013;40:422–30.
Chheda TK, Shivakumar P, Sadasivan SK, et al. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. BMC Gastroenterol. 2014;14:89.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hansen, H.H. et al. (2019). Animal Models of Type 2 Diabetes, Obesity and Nonalcoholic Steatohepatitis – Clinical Translatability and Applicability in Preclinical Drug Development. In: Krentz, A., Weyer, C., Hompesch, M. (eds) Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-11748-1_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-11748-1_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-11747-4
Online ISBN: 978-3-030-11748-1
eBook Packages: MedicineMedicine (R0)